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ABSTRACT
It is well established that transforming growth factor-
 (TGF) switches its function from being a tumor
suppressor to a tumor promoter during the course
of tumorigenesis, which involves both cell-intrinsic
and environment-mediated mechanisms. We are in-
terested in breast cancer cells, in which SMAD mu-
tations are rare and interactions between SMAD
and other transcription factors define pro-oncogenic
events. Here, we have performed chromatin immuno-
precipitation (ChIP)-sequencing analyses which in-
dicate that the genome-wide landscape of SMAD2/3
binding is altered after prolonged TGF stimulation.
De novo motif analyses of the SMAD2/3 binding re-
gions predict enrichment of binding motifs for activa-
tor protein (AP)1 in addition to SMAD motifs. TGF-
induced expression of the AP1 component JUNB
was required for expression of many late invasion-
mediating genes, creating a feed-forward regulatory
network. Moreover, we found that several compo-
nents in the WNT pathway were enriched among
the late TGF-target genes, including the invasion-
inducing WNT7 proteins. Consistently, overexpres-
sion of WNT7A or WNT7B enhanced and potentiated
TGF-induced breast cancer cell invasion, while in-
hibition of the WNT pathway reduced this process.
Our study thereby helps to explain how accumula-
tion of pro-oncogenic stimuli switches and stabilizes
TGF-induced cellular phenotypes of epithelial cells.
INTRODUCTION
The signaling pathways triggered by the transforming
growth factor  (TGF) family members control a wide
range of cellular processes. TGF signals via heterote-
trameric complexes of type I and type II serine/threonine
kinase receptors. The activated receptor complex initi-
ates intracellular signaling by phosphorylating receptor-
regulated (R-) SMAD proteins (SMAD2 and SMAD3).
The activated R-SMADs form heteromeric complexes with
SMAD4, which accumulate in the nucleus and control ex-
pression of target genes (1–3). However, SMADs have rel-
atively weak affinity for DNA and in many cases interact
with so called master transcription factors to achieve high
affinity and target-gene specificity (4,5). These interactions
alter the intensity, duration and specificity of the TGF-
signaling response, in a context- and cell-type-specific man-
ner (6–8).
TGF plays a dual role in tumor progression. In normal
or premalignant cells TGF functions as a tumor suppres-
sor by inhibiting cell proliferation and inducing apoptosis.
However, in late stages of tumor development, TGF in-
stead acts as a tumor promoter by stimulating cell motil-
ity, invasion, metastasis and tumor stem cell maintenance.
This is reflected by the observation that specific types of
cancers are insensitive to the cytostatic effect of TGF due
to inactivation of core components in the TGF pathway
(9,10). On the other hand, in breast cancer and certain other
cancers, defects in the TGF/SMAD signaling itself are
relatively uncommon; instead tumor promoting effects of
TGF/SMAD signaling dominates (reviewed in (11,12)).
In line with this, TGF is frequently overexpressed in breast
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cancer and its expression correlates with poor prognosis and
metastasis (13). The influence of TGF on tumor growth
is also affected by crosstalk between the TGF signaling
pathway and a wide variety of signal transduction path-
ways. For example, the Ras-MAP-kinase (MAPK) path-
way (14) regulates cell migration and invasion synergisti-
cally with TGF (8,11,15,16). Interestingly, transcriptome-
wide analysis of mouse primary hepatocytes treated with
TGF revealed that the early TGF response was charac-
terized by expression of genes involved in cell cycle arrest
and apoptosis, while the late gene signature was associated
with an aggressive and invasive tumor phenotype that effec-
tively identified clinical relevant subgroups of hepatocellu-
lar carcinoma (17).
We previously reported that prolonged stimulation with
TGF induces mesenchymal and invasion-associated genes
through interaction between SMAD and activator protein
(AP)1 components, in particular JUNB (16). AP1 tran-
scription factors are targeted by many signal transduction
pathways and regulate a magnitude of cellular processes,
including cell proliferation, survival, differentiation, inva-
sion and carcinogenesis, depending on their dimer compo-
sition (18–20). SMAD and AP1 members interact at dif-
ferent levels. For example, TGF induces the expression
of specific AP1 components and reporter assays suggested
that the AP1 components JUN and JUNB cooperate with
SMAD2/3 to activate TGF-induced promoters regulated
by AP1 binding sites (21,22), while antagonizing DNA
binding of the same SMADs on promoters controlled by
SMAD binding sites (23). However, little is known about
the SMADs and AP1 crosstalk at the genome-wide level.
Identification and characterization of signaling
molecules that switch TGF/SMAD signaling from
tumor suppression to tumor promotion is critical for the
development of therapies targeting the TGF pathway
(24). To identify SMAD complexes and target genes
involved in tumor progression on a genome-wide scale,
we performed SMAD2/3 chromatin immunoprecipitation
followed by next-generation sequencing (ChIP-seq) and
RNA sequencing analyses, both early and late after TGF
stimulation. Our results indicate that most of SMAD2/3
is redirected to different sites on the genome after pro-
longed TGF treatment. De novo motif analyses predicted
enrichment of binding motifs for AP1 and SMAD, or
the SMAD Binding Element (SBE) consensus sequence
CAGA, in SMAD2/3 binding regions. Moreover, our
results suggest that TGF-induced expression of JUNB
via a positive feed-forward mechanism enables a switch of
the early TGF transcriptional program to a late, invasion-
mediating program. Furthermore, we found that genes
related to WNT signaling pathways are enriched among the
late TGF-target genes. Consistently, modulation of the
WNT signaling pathway aggravated TGF-induced breast
cancer cell invasion and metastasis. Our study thereby
helps to explain how accumulation of oncogenic stimuli
switches TGF responsiveness in epithelial cells.
MATERIALS AND METHODS
Cell culture
Human breast epithelial MCF10A MII cells were obtained
from Dr Fred Miller (Barbara Ann Karmanos Cancer Insti-
tute, Detroit, USA) and maintained at 37◦C and 5% CO2 in
DMEM/F12 (Gibco), supplemented with 5% fetal bovine
serum (FBS) (HyClone), 20 ng/ml epidermal growth fac-
tor (EGF) (PeproTech), 100 ng/ml cholera toxin (Sigma-
Aldrich), 0.5 g/ml hydrocortisone (Sigma-Aldrich), 10
g/ml insulin (Sigma-Aldrich). MCF10A MII cells are de-
rived from MCF10A cells by transformation with Ha-Ras.
Human breast cancer MDA-MB-231 cells and human lung
cancer A549 cells were obtained from ATCC and main-
tained at 37◦C and 5% CO2 in DMEM (Sigma-Aldrich),
supplemented with 10% FBS (Bio West). Breast cancer
Hs578T and BT-549 cells were obtained from ATCC, and
maintained as recommended. Briefly, Hs578T cells were
cultured at 37◦C and 5% CO2 in DMEM (Gibco) sup-
plemented with 10% FBS (HyClone), and 10 g/ml in-
sulin (Gibco), and BT-549 cells were maintained in RPMI-
1640 (Gibco), supplemented with 10% FBS (HyClone), and
0.023 IU/ml insulin (Gibco).
Lentiviral transduction
MCF10A MII cells were infected with lentivirus encod-
ing an shRNA sequence against human JUNB (TRCN00
00014943, TRCN0000014946, TRNC0000014947) selected
from the MISSION shRNA library (Sigma-Aldrich). As a
control an empty pLKO vector was used. Virus transduc-
tion was performed overnight and the infected cells were
selected using culture medium containing Puromycin.
Reagents and antibodies
Recombinant human TGF3 (a generous gift of Dr K.
Iwata, OSI Pharmaceuticals, Inc, New York, USA, or pur-
chased from R&D Systems) was used for stimulation of
cells. Epithelial cells that express betaglycan respond sim-
ilarly to the three TGF isoforms. Recombinant human
WNT7A was from PeproTech. The TGF type I kinase re-
ceptor (TGFRI) inhibitor SB505124 (ALK5i) and IWP-
2 (WNTi), which is an inhibitor of WNT processing and
secretion, were purchased from Sigma-Aldrich and Merck
Millipore, respectively. Puromycin was purchased from In-
vivogen and used at a concentration of 0.5 g/ml. For
siRNA-mediated knockdown, Dharmacon On Target Plus
pools of four oligonucleotides (GE Healthcare Life Sci-
ences) was transfected using siLentFect (Bio-Rad) transfec-
tion reagent according to manufacturer’s instructions at 25
nM final concentration.
Antibodies against the following proteins were used:
ERK1/2 (#4695, Cell Signaling Technology), phospho-
Thr202/Tyr204-ERK1/2 (#4370, Cell Signaling Technol-
ogy), FN1 (F3648, Sigma-Aldrich), JUN (#9164, Cell
Signaling Technology), JUNB (sc-8051, Santa Cruz),
FOS (sc-52, Santa Cruz), FOSB (#2251, Cell Signaling
Technology), FOSL1 (sc-22794, Santa Cruz), FOSL2
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(#610843, BD Transduction Laboratories), phospho-
Ser465/467-SMAD2 (#3108, Cell Signaling Technology),
phospho-Ser423/425-SMAD3 (#9520, Cell Signaling
Technology), SMAD4 (sc-7966, Santa Cruz), -TUBULIN
(sc-8035, Santa Cruz) and WNT7B (AF3460, R&D Sys-
tems). A custom-made JUND antibody was raised in
chicken against a synthetic polypeptide CQLLPQHQV-
PAY, corresponding to the unique C-terminal part of
JUND (Immune Systems).
Plasmid construction
WNT7A and WNT7B cDNAs were kindly provided by Dr
Brad St. Croix. For stable cell line establishment, cDNAs
were cloned into an episomal expression vector pPyCAG-
IRES-Puro, which contains polyoma Ori and can be prop-
agated episomally in cells (25).
Western blot analysis
MCF10A MII cells were seeded in 6-well-plates (2.5 × 105
cells/well), and starved the following day for 16 h in 0.2%
FBS, and cells were then stimulated with 5 ng/ml of TGF3
for indicated time-periods. Cells were lysed in 2× SDS
Laemmli sampler buffer (5% SDS, 25% glycerol, 150 mM
Tris–HCl pH 6.8, 0.01% bromophenol blue, 100 mM dithio-
threitol (DTT)). Samples were separated by SDS-PAGE,
blotted onto nitrocellulose membrane (Amersham Protran,
GE Healthcare Life Science), and the chemiluminescent sig-
nal was detected using the Immobilon Western kit (Merck
Millipore).
3D spheroid collagen invasion assay
One thousand cells, of the indicated cell line, were
trypsinized, re-suspended in medium containing 2.4 mg/ml
methylcellulose (Sigma-Aldrich) and added into each well
of a U-bottom 96-well-plate (Greiner Bio One) allowing the
formation of one spheroid per well. Two days after plat-
ing, a U-bottom 96-well-plate was coated with neutralized
bovine collagen-I (PureCol, Advanced BioMatrix) accord-
ing to manufacturer’s protocol. Spheroids were harvested
and embedded in a 1:1 mix of neutralized collagen and
medium supplemented with 12 mg/ml of methylcellulose
and allowed to polymerize on the top of the neutralized
collagen. TGF3 and/or recombinant WNT7A were di-
rectly added to the embedding solution. After polymeriza-
tion, medium supplemented with 1.6% FBS was added to
the top of the collagen. SB505124 and IWP-2 were added
in the medium. Pictures were taken at day 0 and day 2 after
embedding and quantified by measuring the area occupied
by cells using Adobe Photoshop CS3 software.
Zebrafish maintenance
This study was approved by The Institutional Committee
for Animal Welfare of the Leiden University Medical Cen-
ter (LUMC). Zebrafish and embryos were maintained ac-
cording to standard procedures. The transgenic fish line
Tg(fli1:GFP) was used in this study as described before
(26,27). All experiments were performed in accordance with
approved guidelines and regulations.
Embryo preparation and tumor cell implantation
Tg(fli1:GFP) zebrafish embryos were dechorionated at 2
days post fertilization (dpf). Single cell suspensions of
mCherry labelled MCF10A MII, MDA-MB-231 or A549
cells were re-suspended in PBS and kept at 4◦C before in-
jection. Cell suspensions were loaded into borosilicate glass
capillary needles (1 mm O.D. × 0.78 mm I.D.; Harvard
Apparatus). Injections were performed with a Pneumatic
Picopump and a manipulator (WPI). Dechorionated em-
bryos were anaesthetized with 0.003% tricaine (Sigma) and
mounted on 10-cm Petri dishes coated with 1% agarose.
Approximately 400 cells were injected at the duct of Cu-
vier (DOC). Injected zebrafish embryos were maintained at
34◦C. All the experiments were repeated at least two times
and at least 30 embryos were analyzed per group.
Microscopy and analysis
Six days post infection (dpi) embryos were fixed with 4%
paraformaldehyde at 4◦C overnight. Fixed embryos were
analyzed and imaged in PBS with a Leica SP5 STED con-
focal microscope (Leica). The numbers of clusters formed
in caudal hematopoietic tissue (CHT) of each embryo were
counted. Confocal stacks were processed for maximum in-
tensity projections with matched software LAS AF Lite.
Brightness and contrast of images were adjusted as well.
RNA isolation, cDNA synthesis and quantitative real time-
PCR (qRT-PCR)
Total RNA was isolated by RNeasy Kit (Qiagen). cDNA
was prepared by using iScript kit (Bio-Rad) using 0.5 g
of total RNA, according the manufacturer’s instructions.
The cDNA samples were diluted 10 times in water. qRT-
PCR was performed using KAPA SYBR FAST qPCR kit
Master Mix (KAPA Biosystems) and BioRad CFX96 real-
time PCR detection system according the manufacturer’s
instructions. qRT-PCR reactions were performed as follow:
one cycle of 95◦C for 10 min followed by 40 cycles of 95◦C
for 15 s and 60◦C for 30 s, followed by one cycle of 95◦C
for 15 s and 65◦C for 5 s. Relative gene expression was de-
termined using the Ct method. The expression was nor-
malized to the GAPDH gene and quantified relative to the
control condition. The complete primers list can be found
in Supplementary Table S1 in the Supplementary Data.
Chromatin immunoprecipitation (ChIP)
Cells were cultured in 10-cm plates to ∼80–90% confluence,
and one plate was used per immunoprecipitation. Cells
were fixed in 1% formaldehyde for 10 min at room tem-
perature with swirling. Glycine was added to a final con-
centration of 0.125 M, and the incubation was continued
for an additional 5 min. Cells were washed twice with ice-
cold phosphate-buffered saline, harvested by scraping, pel-
leted, and resuspended in 1 ml of SDS lysis buffer (50 mM
Tris–HCl, pH 8.0, 1% SDS, 10 mM EDTA, protease in-
hibitors (Complete EDTA-free protease inhibitors; Roche
Diagnostics)). Samples were sonicated three times for 30 s
each time (output H) at intervals of 30 s with a Diagenode
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rpm at 4◦C for 10 min. After removal of a control aliquot
(whole-cell extract), supernatants were diluted 10-fold in
ChIP dilution buffer (20 mM Tris–HCl, pH 8.0, 150 mM
NaCl, 2 mM EDTA, 1% Triton X-100). Samples were in-
cubated at 4◦C overnight in 2-methacryloyloxyethyl phos-
phorylcholine polymer-treated 15-ml polypropylene tubes
(Assist, Japan) with anti-mouse IgG-Dynabeads that had
been preincubated with 5 g of anti-SMAD2/3 antibody in
phosphate buffered saline, 0.5% bovine serum albumin. The
beads were then moved to 1.7-ml siliconized tubes (#3207;
Corning) and washed five times with ChIP wash buffer (50
mM HEPES–KOH, pH 7.0, 0.5 M LiCl, 1 mM EDTA,
0.7% deoxycholate, 1% Igepal CA630) and once with TE
buffer, pH 8.0. Immunoprecipitated samples were eluted
and reverse cross-linked by incubation overnight at 65◦C in
elution buffer (50 mM Tris–HCl, pH 8.0, 10 mM EDTA,
1% SDS). Genomic DNA was then extracted with a PCR
purification kit (Qiagen). The immunoprecipitated DNA
was analyzed by qRT-PCR using locus specific primers (the
complete primers list can be found in Supplementary Ta-
ble S2 in the Supplementary Data) and normalized to in-
put DNA. Relative fold enrichment corresponded to the
SMAD2/3 enrichment in each locus divided by the enrich-
ment in the negative control regions (hemoglobin β (HBB)
promoter and HPRT1 first intron) and quantified relative
to the control- or the siNTC-condition as indicated.
ChIP-sequencing (ChIP-seq) and data analysis
Chromatin isolation, sonication and immunoprecipitation
using anti-SMAD2/3 antibody were performed essentially
as described (28,29). The library was prepared using NEB-
Next ChIP-Seq Library Prep Reagent Set for Illumina
(New England Biolabs), KAPA DNA Library Preparation
Kits for Illumina (KAPA Biosystems), or IonXpress Plus
Fragment Library Kit (Thermo Fisher Scientific). High-
throughput sequencing of the ChIP fragments was per-
formed using Genome Analyzer IIx or HiSeq 2000 (Il-
lumina) or Ion Proton sequencer (Thermo Fisher Scien-
tific) following the manufacturer’s protocols. Reference files
of the human reference sequence assembly (NCBI Build
37/hg19, February 2009) and GTF annotation file were
obtained from iGenomes (http://support.illumina.com/
sequencing/sequencing software/igenome.html). All ChIP-
seq data sets were aligned using Bowtie (version 1.1.0) (30)
with the command ‘-S -a –best –strata -v 1 -m 1’. SMAD2/3
binding regions were identified using MACS software
(Model based analysis of ChIP-seq) (version 1.4.2) (31) with
a P-value threshold of 1e-5. Assigning a binding site to the
nearest gene within 100 kb from a peak was performed us-
ing CisGenome ver2 (32). De novo motif prediction was per-
formed by MEME-ChIP with a slight modification of the
default settings (maximum width: 10) (MEME-ChIP ver-
sion 4.10; http://meme.nbcr.net/meme/cgi-bin/meme-chip.
cgi) (33). The logo plots were generated using the R pack-
age seqLogo. Mapping of TFBSs to the specific genomic
regions were calculated by the CisGenome. Gene Ontol-
ogy (GO) enrichment analysis was performed using the
Database for Annotation, Visualization, and Integrated
Discovery (DAVID v6.7; http://david.abcc.ncifcrf.gov) (34).
Biological functions associated with the SMAD2/3 bind-
ing sites were predicted using GREAT (Genomic Regions
Enrichment of Annotations Tool) (35). The ChIP-Seq data
of H3K4me1, H3K4me3 and corresponding control input
DNA of MCF10A cells (SRA045635) (36) were obtained
from the Sequence Read Archive (SRA) (http://www.ncbi.
nlm.nih.gov/sra). The ChIP-Seq data of H3K4me1 and
H3K4me3 of HMEC were generated and available from
ENCODE consortium (37).
RNA-sequencing (RNA-seq) and data analysis
RNA-seq libraries were prepared essentially as described
(38). In short, mRNA was isolated from 1 g total RNA
using Dynabeads Oligo(dT)25 (Life Technologies) and frag-
mented to 150–200 nt in first strand buffer for 3 min at 94◦C.
Random hexamer primed first strand was generated in pres-
ence of dATP, dGTP, dCTP and dTTP. Second strand was
generated using dUTP instead of dTTP to tag the sec-
ond strand. Subsequent steps to generate the sequencing li-
braries were performed with the NEBNext kit for Illumina
sequencing (New England Biolabs) with minor modifica-
tions; after indexed adapter ligation to the dsDNA frag-
ments, the library was treated with USER (Uracil-Specific
Excision Reagent) Enzyme (New England Biolabs) in order
to digest the second strand derived fragments. After ampli-
fication of the libraries, samples with unique sample indexes
were pooled and sequenced using HiSeq 2000 with TruSeq
SBS Kit v3 reagent or HiSeq 2500 with TruSeq SBS Kit v4
reagent (Illumina) following the manufacturer’s protocols.
Gene expression levels in fragments per kilobase of exon
per million fragments mapped (FPKM) were estimated us-
ing Tophat/Cufflinks (version 2.0.13 and 2.2.1, respectively)
with the default parameter settings (39). For the analysis
and visualization of the data generated by Cufflinks, we
used the R package cummeRbund.
Analysis of Breast Cancer clinical datasets
For the analysis of patient datasets from Molecular
Taxonomy of Breast Cancer International Consortium
(METABRIC) (40), all statistical tests were performed us-
ing R software (version 3.2.5, https://www.r-project.org/)
as described previously (41). Z-scored expression values of
mRNA were obtained from cBioPortal (42,43) in Septem-
ber 2017. Patients were divided into low and high expressers
using the median values of mRNA expression. The overall
survival was estimated with the Kaplan-Meier method and
differences between groups were evaluated by the log-rank
test, using the R package cmprsk. P-values were calculated
using Welch’s t-test, or unequal variance t-test (*P < 0.05,
**P < 0.01, ***P < 0.001).
Meta-analysis of Breast Cancer datasets were performed
using KM plotter (http://kmplot.com) (44) with default set-
tings; all subtypes, n = 3557; ER+ subjects, n = 2036; ER-
subjects, n = 807; luminal A subtype, n = 2069; luminal
B subtype, n = 1166; HER2-subtype, n = 239; basal-like
subtype, n = 668), and the data sets includes E-MTAB-365,
GSE11121, GSE12093, GSE12276, GSE1456, GSE16391,
GSE16446, GSE17705, GSE17907, GSE19615, GSE20194,
GSE20271, GSE2034, GSE20685, GSE20711, GSE21653,
GSE2603, GSE26971, GSE2990, GSE31448, GSE31519,
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Gene set enrichment analysis (GSEA)
Gene set enrichment analysis (GSEA) analy-
ses were performed using the tool available at
http://www.broadinstitute.org/gsea/index.jsp (45). In
brief, fold change (log2) in gene expression from two
experimental conditions were calculated and the list was
then used as a ranked list in the Pre-Ranked function of
the GSEA software.
Statistical analysis
For ChIP-qPCR and qRT-PCR at least three independent
experiments were performed and results are shown by dot
plot chart. The differences between experimental groups
were analyzed using Welch’s t-test, with *P < 0.05, **P <
0.01 and ***P < 0.001 being considered significant. Col-
lagen invasion assays contained n ≥ 6 spheroids for each
condition, and was repeated at least twice with similar re-
sults. Data are presented as means ± SD. The differences
between experimental groups were analyzed using Welch’s
t-test, with *P < 0.05, **P < 0.01 and ***P < 0.001 be-
ing considered significant. For the zebrafish experiments
statistical analysis was performed using Prism 4 software
(GraphPad La Jolla, USA). Results are expressed as the
mean ± SEM. Student’s t-test or one-way analysis of vari-
ance (ANOVA) were performed followed by the Tukey’s
method for multiple comparison. P < 0.05 was considered
to be statistically significant (*0.01 < P < 0.05, **0.001 <
P < 0.01, ***P < 0.001).
RESULTS
SMAD2/3 are redirected to different sites after prolonged
TGF treatment
To identify both early and late SMAD-containing com-
plexes and target genes involved in tumor progression,
we first conducted SMAD2/3 ChIP-seq in MCF10A MII
breast cancer cells after 1.5 and 16 h of TGF treatment.
Analysis of three well known TGF/SMAD target genes,
SERPINE1, laminin β (LAMB)3 and matrix metallopro-
tease (MMP)2, as expected, showed enriched SMAD2/3
binding in specific regions of the gene loci, including the
SMAD2/3 binding site that was previously identified in the
SERPINE1 promoter in HaCaT keratinocytes (46) (Figure
1A). TGF-dependent SMAD2/3 binding to these three
genes was also detected by ChIP-qPCR analysis (Supple-
mentary Figure S1A). Interestingly, at the late time point
SMAD2/3 was found to bind to different regions of the
SERPINE1 and LAMB3 loci, whereas in the MMP2 gene
locus SMAD2/3 binding to the binding site located 40 kb
upstream of the transcription start site (TSS) was lost (Fig-
ure 1A). Moreover, overall SMAD2/3 recognized more tar-
get sites after 16 h of TGF stimulation (3280 sites) com-
pared to 1.5 h stimulation (2206 sites), and only ∼700
SMAD2/3 binding sites overlapped between the two time
points (Figure 1B), suggesting that the activated SMAD2/3
proteins (Figure 1C) were redirected to different binding
sites over the genome at the late time point. Furthermore,
there were no differences in preferences of SMAD2/3 bind-
ing sites on the genome between the two conditions; ∼35%
of the SMAD2/3 binding sites were located in the introns
of known genes and ∼10% in the promoter regions within
10 kb upstream of known TSSs (Figure 1D).
We next compared our SMAD2/3 binding data with pre-
viously reported enhancer data in non-stimulated normal
human mammary epithelial cells (HMEC) and parental
MCF10A cells (36,37). The SMAD2/3 binding sites shared
between cells stimulated 1.5 and 16 h overlapped well with
the previously identified enhancer regions characterized by
H3K4me1 (Figure 1E and Supplementary Figure S1B).
The 1.5 h-only sites also overlapped with these H3K4me1
marks, but the 16 h-only sites did not (Figure 1E and
Supplementary Figure S1B). In contrast, fewer SMAD2/3
peaks overlapped with the previously reported promoter re-
gions characterized by H3K4me3. This could mean that af-
ter 1.5 h TGF stimulation, SMAD2/3 preferentially binds
to enhancer regions already accessible in non-stimulated
normal mammary epithelial cells, but after 16 h prefers dif-
ferent regions. In fact, distinct gene ontologies (GOs) were
enriched in the genes associated with 16 h-only sites com-
pared with those of 1.5 h-only sites (Supplementary Figure
S1C).
To validate whether the changes in SMAD2/3 binding
indeed result in changes in target gene programs, we per-
formed RNA-seq transcriptome analysis after short (1.5 h)
and long (16 h) periods of TGF stimulation of MCF10A
MII cells and compared with unstimulated cells. Consis-
tent with the SMAD2/3 binding profiles, RNA-seq data
revealed that more genes were strongly induced at the late
time point compared to the early time point (Figure 2A).
Gene set enrichment analysis (GSEA) based on Kyoto en-
cyclopedia genes and genomes (KEGG)-defined pathways
confirmed that genes associated with GOs like the TGF
signaling pathway were enriched among the early TGF
target genes with SMAD2/3 binding sites, whereas genes
within Focal adhesion and MAPK signaling pathways were
enriched among the late TGF target genes (Figure 2B–E).
JUNB is a critical AP1 component for SMAD2/3 binding
after TGF stimulation
An explanation for the changes in SMAD2/3 binding at
16 h might be that DNA binding factors that are modu-
lated by TGF-SMAD signaling at early time points subse-
quently redirect SMAD2/3 to different binding sites on the
genome as a part of a feed-forward loop, e.g. by interacting
with SMAD2/3 and/or affecting its chromatin accessibility.
To obtain more clues on this, we performed de novo motif
prediction analysis. Interestingly, AP1 binding motifs were
identified as the major recognition elements among both the
early and late sites, with higher significance than SBEs (Fig-
ure 3A).
We next analyzed the expression profiles of AP1 at pro-
tein and mRNA levels (Figures 3B and Supplementary Fig-
ure S2A). Both JUN, JUNB, FOS, FOSB and FOSL2 were
strongly induced after TGF treatment, while FOSL1 was
suppressed at the mRNA level but unaffected at the pro-
tein level, in line with our previous findings (16). Moreover,
in these cells JUNB was most critical for TGF-induced
invasion as well as induction of some invasion-associated
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Figure 1. SMAD2/3 are redirected to different sites in MCF10A MII after prolonged TGF treatment. (A) Genomic loci of SERPINE1 (plasminogen
activator inhibitor 1, or PAI-1), MMP2 and LAMB3 genes are shown together with the results of SMAD2/3 ChIP-seq data. The direction of transcription
is shown by the arrow beginning at the transcription start site (TSS). Statistically significant regions are marked by a gray-colored box. (B) A Venn diagram
indicating overlap of SMAD2/3 binding sites of MCF10A MII cells after 1.5 and 16 h TGF (5 ng/ml) treatment. The numbers of overlapped regions are
not identical, since some of the peaks are not on a one-by-one correspondence. (C) Western blots for phospho-SMAD2/3 in MCF10A MII cells after 0,
1.5 and 16 h TGF (5 ng/ml) treatment. (D) Distribution of SMAD2/3 binding sites in MCF10A MII cells relative to known genes in the human genome
(hg19). (E) Heat map representation of the location of the indicated histone marks in breast HMEC and MCF10A epithelial cells within the 10-kb region
surrounding the center of the SMAD2/3 peaks. SMAD2/3 binding sites were ordered based on the strength of binding (y axis). The presence of epigenetic
marker (36,37) is displayed.
tion occurred in 1–14% of breast cancer patients (Supple-
mentary Figure S2B) (40,42,43). In addition, patients with
JUNB amplification had a trend of poorer prognosis (Sup-
plementary Figure S2C), although this was not statistically
significant because of the small number of cases. We there-
fore decided to functionally assess the role of JUNB in the
recruitment of SMAD2/3 to the late TGF-induced gene
program.
We first analyzed again the three well known
TGF/SMAD target genes, SERPINE1, LAMB3,
and MMP2. Knock-down of JUNB strongly inhibited the
recruitment of SMAD2/3 to the SERPINE1 and LAMB3
gene loci after 16 h of TGF stimulation (Figure 3C and
Supplementary Figure S2D), while SMAD2/3 recruitment
to the MMP2 gene locus was not affected. Moreover,
knock-down of JUNB inhibited TGF-induced mRNA
expression of SERPINE1 and LAMB after prolonged
TGF stimulation, but not of MMP2, and phosphoryla-
tion of SMAD 2 and 3 was hardly influenced (Figure 3D).
The late JUNB-dependent binding of SMAD2/3 to the
SERPINE1 and LAMB3 gene loci (Figure 3C and Supple-
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Figure 2. Identification of a late TGF target gene signature. (A) Scatter plot representing fold change after TGF (5 ng/ml) treatment. Each point
represents values of a gene. Genes with a SMAD2/3 binding within 50 kb from gene bodies after 16 h TGF treatment are colored red. A dot square
represents 2-fold change of gene expression. (B–E) Gene set enrichment analysis (GSEA) of expression changes of SMAD2/3 target genes after 1.5 h (B
and C) and 16 h (D and E) of TGF (5 ng/ml) treatment. The SMAD2/3 target genes were pre-rank-ordered according to their fold change (log2) after
TGF treatment for the indicated time periods, and analyzed based on KEGG signaling pathway enrichment. Gene sets with a P-value < 5% and an FDR
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Motifs identified in SMAD2/3 ChIP-seq
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Figure 3. JUNB is a critical AP1 component for SMAD2/3 binding after TGF stimulation. (A) Motifs enriched in the SMAD2/3 binding sites. Motifs
which resemble the motif of AP1 were identified as well as SBE. (B) Western blots of various AP1 components in MCF10A MII cells after no TGF
treatment (–), or TGF (5 ng/ml) treatment for 1.5 or 16 h. (C) ChIP-qPCR showing SMAD2/3 binding to the indicated gene loci in MCF10A MII
cells transfected with non-targeting control (siNTC) or specific JUNB siRNA and stimulated for 16 h with TGF (5 ng/ml). Results of five independent
experiments are shown by dot plot chart; ***P < 0.001 versus siNTC. (D) qRT-PCR analysis (top) and Western blot control (bottom) to investigate the
role of JUNB in TGF-induced gene expression. MCF10A MII cells were transfected with non-targeting control (siNTC) or specific JUNB siRNA and
stimulated for 1.5 or 16 h with TGF (5 ng/ml). Results of five independent experiments are shown by dot plot chart; *P < 0.05, **P < 0.01. (E) ChIP-
qPCR showing time-dependent recruitment of JUNB to the indicated gene loci in MCF10A MII cells before (–) or after TGF treatment (1.5 or 16 h).
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of JUNB to the same gene loci (Figure 3E). Based on
these results, we hypothesized that JUNB may determine
the target- and time-specificity of SMAD complexes as a
co-binding factor for a specific subset of invasion genes.
A JUNB-mediated feed-forward mechanism regulates genes
associated with cell adhesion and invasion, and controls inva-
sion in zebrafish xenograft models
To characterize the significance of JUNB for TGF-
SMAD-target genes on a genome-wide scale, we performed
RNA-seq transcriptome analysis in JUNB-knock-down
MCF10A MII cells (Figure 4A and Supplementary Fig-
ure S3A). We found that several well-characterized TGF-
SMAD-target genes associated with cell adhesion, invasion
and mesenchymal phenotype, e.g. fibronectin (FN)1 and
integrin α (ITGA)2, were dependent on JUNB-induction
(Supplementary Figure S3B), which was also confirmed by
GO analysis (Supplementary Figure S3C). Interestingly, 20
genes appeared in the core-enriched genes of the pathway
‘Pathways in cancer’ in GSEA analysis (Figure 4B and C),
at least 8 of which, FN1, ITGA2, ITGA6, LAMA3, LAMB3,
LAMC2, collagen (COL)4A1, and COL4A2, are known
target genes of TGF (8,47–49). In addition, genes in the
WNT signaling pathway were enriched, which is discussed.
Taken together, the gene set analysis presented above,
and the observation that JUNB is required for efficient ex-
pression of selected TGF-SMAD-target genes associated
with cell invasion and mesenchymal phenotype ((16), Fig-
ures 3D and 4C), suggest that a late SMAD/JUNB-induced
gene program is critical for TGF-induced invasion and
cancer progression. In line with this hypothesis, we pre-
viously found transient siRNA-mediated knock-down of
JUNB to result in strongly reduced TGF-induced inva-
sion of MCF10A MII spheroids in collagen (16). To fur-
ther validate these data, we stably knocked down JUNB
with lentiviral vectors, which showed that decreased levels
of JUNB correlate with decreased collagen invasion (Fig-
ure 4D). To examine the importance of JUNB in breast
cancer cell invasion in vivo, we used an embryonic zebrafish
xenograft invasion model (27). We have previously demon-
strated that TGF signaling is critical for MCF10A MII
invasion in this model (50). Importantly, knock-down of
JUNB with siRNA resulted in reduced invasion compared
to non-targeting siRNA control groups (Figure 4E). More-
over, knock-down of JUNB also resulted in reduced ze-
brafish invasion of the TGF-dependent metastatic human
breast cancer cell line MDA-MB-231 (51,52) (Figure 4F).
These results confirm that JUNB is important for breast
cancer invasion.
Since tumorigenesis is a long-term event, we next veri-
fied whether a more extended TGF exposure, up to 72
h, results in a similar ‘late-stage’ TGF-induced gene ex-
pression program as 16 h treatment. As exemplified in
Supplementary Figure S4A, the data obtained for these
later time points were consistent with the data obtained
at 16 h. In addition, since we identified the mesenchymal
marker fibronectin as one of the main JUNB-dependent
genes (Figure 4A, C and Supplementary Figure S3B), we
examined the effect of JUNB depletion in the human pul-
monary adenocarcinoma cancer cell line A549, which un-
dergoes epithelial-mesenchymal transition (EMT) in re-
sponse to prolonged TGF stimulation. The expression
of various TGF-induced mesenchymal and/or EMT con-
trolling genes was severely reduced by JUNB knock-down
in these pulmonary adenocarcinoma cells (Supplementary
Figure S4B), and JUNB was also found to be critical for in-
vasion of A549 cells in the zebrafish xenograft model (Sup-
plementary Figure S4C), This further confirms the pro-
oncogenic protential of JUNB in TGF induced invasion.
Activation of the WNT signaling pathway strengthens the
TGF-induced migratory phenotype
Interestingly, we also found that genes related to the WNT
signaling pathway were enriched among the late TGF tar-
get genes, in addition to the genes associated with adhesion
and invasion (Figures 2E and 4B). We therefore focused
on the most prominent JUNB-dependent WNT pathway
and breast cancer associated gene in the list, WNT7B, and
examined its importance in TGF-induced cell migration
and invasion. Our SMAD2/3 ChIP-seq and -qPCR analysis
showed enhanced TGF-induced binding of SMAD2/3 to
the WNT7B locus in a time-dependent manner (Figure 5A
and Supplementary Figure S5A). In line with this, WNT7B
expression was preferably induced after prolonged TGF-
treatment (Figure 5B). Moreover, WNT7B was induced af-
ter prolonged TGF stimulation in a SMAD4- and JUNB-
dependent manner (Figure 5C). The late JUNB-dependent
expression of WNT7B and the time-dependent recruitment
of SMAD2/3 to the WNT7B locus (Figure 5A), correlated
with enhanced binding of JUNB to the same gene locus af-
ter 16 h of TGF stimulation (Figure 5D). Together, these
results identify WNT7B as a JUNB-mediated late TGF-
SMAD-target gene.
To directly test if WNT7B is important for TGF-
induced invasion, we performed collagen invasion assays.
Addition of the TGF type I kinase receptor (TGFRI)
inhibitor SB505124 almost completely blocked TGF-
induced collagen invasion of MCF10A MII spheroids,
as expected (Figure 5E). Addition of the general WNT-
inhibitor IWP-2 (53) also significantly inhibited TGF-
induced invasion. To directly evaluate the role of WNT7B,
we generated MCF10A MII cells stably expressing WNT7B
(Supplementary Figure S5B). Exogenous expression of
WNT7B enhanced both basal and TGF-induced inva-
sion (Figure 5E). Consistent with this finding, addition
of recombinant WNT7A, which was also one of the late
TGF target genes (Figure 4C) and shares 82% amino
acid identity with WNT7B, or expression of WNT7A, en-
hanced both basal and TGF-induced invasion (Supple-
mentary Figure S5C and S5D). Interestingly, addition of
the TGFRI inhibitor SB505124 strongly inhibited TGF-
induced invasion also in WNT7B expressing cells (Figure
5E), suggesting that WNT7B stabilizes the TGF-induced
migratory phenotype of epithelial cells, rather than merely
functioning as a downstream mediator of TGF signal-
ing. In line with this notion, we found enhanced levels of
TGF-induced phospho-SMAD2 and 3 in WNT7B over-
expressing cells, whereas the general WNT-inhibitor IWP-
2 reduced this phosphorylation, and also in the parental
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Figure 4. A JUNB-mediated feed-forward mechanism regulates genes associated with cell adhesion, invasion and controls invasion in a zebrafish model.
(A) Scatter plot representing fold change after TGF (5 ng/ml) treatment. Each point represents values of a gene. Genes whose induction after 16 h
TGF (5 ng/ml) treatment was attenuated more than 50% with siJUNB treatment are colored red. (B) GSEA of expression changes of SMAD2/3 target
genes after manipulation of JUNB expression. The SMAD2/3 target genes were pre-rank-ordered according to their fold change (log2) between siNTC
and siJUNB, and analyzed based on KEGG signaling pathway enrichment. Gene sets with P-value < 5% and FDR q-value < 25% were considered
significant. Enrichment score (ES) is plotted on the y axis. (C) A list of core-enriched genes of the pathway ‘Pathways in cancer’, which contribute most
to the enrichment score of the pathway. (D) Stable knock-down of JUNB in MCF10A MII cells with three distinct shJUNB expressing lentiviral vectors.
Whereas #1 is efficient, #3 does not inhibit JUNB expression. Left: Western blot analysis. Right: collagen invasion of MCF10A MII spheroids stably
expressing the sh control (Ctrl) or three distinct shJUNB lentiviral constructs. Spheroids were embedded in collagen in the absence or presence of TGF (5
ng/ml) as indicated. Relative invasion was quantified as the mean area that the spheroids occupied 36 h after being embedded in collagen. Data represent
means ± SD (n ≥ 6 spheroids per condition) and are representative of three independent experiments; ***P < 0.001. (E and F) MCF10A MII (E) or
MDA-MB-231 (F) mCherry cells transfected with non-targeting control (siNTC) or specific JUNB siRNA (siJUNB) were injected into the ducts of Cuvier
(DoC) of 48 h post-fertilization (hpf) zebrafish embryos. Left: representative images of zebrafish at 6 days post-injection (dpi). Right: quantification of
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Figure 5. Activation of the WNT signaling pathway strengthens the TGF-induced migratory phenotype. (A) ChIP-qPCR showing time-dependent
recruitment of SMAD2/3 binding to the WNT7B gene locus in MCF10A MII before (–) or after TGF (5 ng/ml) treatment (1.5 and 16 h). Results of
four independent experiments are shown by dot plot chart; *P < 0.05. (B) qRT-PCR analysis showing time-dependent WNT7B mRNA expression in
MCF10A MII before (–) or after TGF (5 ng/ml) treatment (1.5 or 16 h). Results of six independent experiments are shown by dot plot chart; **P < 0.01.
(C) Left: qRT-PCR analysis of WNT7B mRNA expression in MCF10A MII cells transfected with the indicated control (siNTC) or JUNB and SMAD4
specific siRNAs, and stimulated for 16 h with TGF (5 ng/ml). Results of four independent experiments are shown by dot plot chart; **P < 0.01 versus
siNTC TGF 16 h. Right: Western blot control of knock-down efficiency. (D) ChIP-qPCR showing time-dependent recruitment of JUNB to the WNT7B
gene locus in MCF10A MII before (–) or after TGF (5 ng/ml) treatment (1.5 and 16 h). (E) Collagen invasion assay of MCF10A MII spheroids stably
expressing control GFP or ectopic WNT7B-MYC. Spheroids were embedded in collagen in the absence or presence of TGF, the TGFRI inhibitor
(ALK5i) SB505124 (2.5 M) or the WNT inhibitor (WNTi) IWP-2 (5 M), as indicated. Left: representative pictures of spheroids taken 36 h after being
embedded in collagen. Right: relative invasion was quantified as the mean area that the spheroids occupied 36 h after being embedded in collagen. Data
represent means ± SD (n ≥ 6 spheroids per condition) and are representative of three independent experiments; ***P < 0.001. (F) Western blot analysis of
the MCF10A MII cells stably expressing control GFP or ectopic WNT7B-MYC. Cells were treated for 12 h with TGF (5 ng/ml) in the absence or presence
of DMSO control, the TGFRI inhibitor (ALK5i) SB505124 (2.5 M) or the WNT inhibitor (WNTi) IWP-2 (5 M), as indicated. (G) qRT-PCR target
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cells contained increased levels of activated phosphorylated
ERK1/2 and the expression of various TGF/SMAD-
induced invasion genes was enhanced (Figure 5G). This in-
dicates that WNT7B increases invasion/migration to a large
extent by enhancing TGF type I receptor mediated signal-
ing.
WNT7B promotes breast cancer cell invasion
To investigate the role of WNT7B in invasion and metasta-
sis in vivo, we again used the zebrafish embryo xenograft
model. Embryos injected with MCF10A MII cells stably
expressing WNT7B showed a significant increase in inva-
sive cell numbers compared to control cells (Figure 6A).
This result demonstrates that WNT7B expression stimu-
lates MCF10A MII invasion in zebrafish.
To further address the clinical significance of WNT7B
expression in breast cancers, we analyzed patient datasets
from the Molecular Taxonomy of Breast Cancer Inter-
national Consortium (METABRIC) (40). We found that
higher expression of the WNT7B gene was linked with
shorter overall survival (Figure 6B). Moreover, high ex-
pression of WNT7B correlated with poorer prognosis in
a cohort of ER+ tumors, especially in those of luminal
type, but not of basal-like or triple negative breast cancers
(TNBC). The WNT7B-high subgroup had higher mRNA
expression of FN1 and COL1A1, well-established markers
for the mesenchymal phenotype or tumor invasiveness (Fig-
ures 4A and 6C). In addition, we performed in silico meta-
analysis of published microarray datasets using the Kaplan-
Meier plots website (44), which also indicated that mRNA
expression of WNT7B predicted poorer outcome especially
in ER+ patients (Supplementary Figure S6A).
To verify whether ER-negative tumor cells have a similar
genome-wide SMAD2/3 binding landscape as ER+ cells,
we performed SMAD2/3 ChIP-seq analysis in the TNBC
lines Hs-578-T and BT-549 (Supplementery Figure S6B). In
Hs-578-T cells SMAD2/3 did not bind the WNT7B locus
(Supplementery Figure S6B), while SMAD2/3 binding was
observed in the WNT7B locus of BT-549 cells. However, in
contrast to MCF10A MII cells, the number of SMAD2/3
binding sites was higher at 1.5 h than at 16 h with about 50%
overlap (Supplementary Figure S6C). Moreover, although
the AP1 motif was enriched in the SMAD2/3 binding sites
in BT-549 (Supplementary Figure S6D), the data suggests
that there is no JUNB-mediated redirection of SMAD2/3
in BT-549. Thus, our data showed heterogeneity among the
TNBC cell lines.
The selective association in the ER+ group may be ex-
plained by the finding that TGF mainly functions as a tu-
mor suppressor in the ER+ group, but as a tumor promoter
in the ER- group of the breast cancer patients (13). Our data
thus suggest that inhibition of the JUNB-mediated feed-
forward loop may restore the tumor suppressive roles of
TGF. It also implies that the feed-forward loop and/or ac-
tivation of WNT7B signaling pathway may be a biomarker
for the use of TGF inhibitors for tumor treatment.
DISCUSSION
It is well established that during the later stages of tumori-
genesis TGF promotes tumor progression by enhancing
migration, invasion and survival of tumor cells, by stim-
ulating extracellular matrix deposition and tissue fibrosis,
perturbing immune surveillance, stimulating angiogenesis
and promoting EMT (8,11,15). One of the contributing fac-
tors is the effect of TGF on the tumor microenvironment,
which in turn affects the tumor cells. In addition, sequen-
tial acquisition of genomic mutations changes the TGF
responsiveness of cancer cells in a cell-intrinsic manner (54).
For instance, in pancreatic cancer where SMAD4 mutations
are common, loss of SMAD4 enables escape from cyto-
static TGF effects or lethal effects associated with TGF-
induced-EMT (55). In breast cancer cells, however, SMAD
mutations are rare (56,57). This suggests that DNA-binding
co-factors for SMADs, including JUNB, cause quantitative
and/or qualitative changes in SMAD signaling and thereby
play essential roles in the switch of the cancer-associated
functions of TGF, from cytostasis/apoptosis to tumor-
promotion.
We have previously demonstrated that SMAD3, SMAD4
and the AP1 components JUN, JUNB, FOS and FOSL1
cooperatively regulate several established TGF-target
genes with a known function in EMT and invasion, in-
cluding MMP1, MMP9, SNAI1 and SERPINE1, and en-
hance TGF-induced collagen invasion of MCF10A MII
spheroids (16). The ChIP-seq and RNA-seq analyses in the
current study show that the strong and prolonged induction
of JUNB by TGF redirects SMAD2/3 to different target
sites and thereby plays a major role in the activation of late
TGF target genes as critical component of a feed-forward
regulatory network. Interestingly, AP1 has previously been
reported to potentiate chromatin accessibility of the gluco-
corticoid receptor (GR) in a murine mammary epithelial
cells (58), and in human breast cancer cells to colocalize on
the genome with YAP/TAZ/TEAD, Hippo pathway trans-
ducers and transcription factors (59). Since critical roles
of AP1 components in breast cancer have been well docu-
mented, especially in the aggressive clinical subtype TNBC
(60), induction of AP1 by TGF may potentiate aggressive
phenotypes of breast cancer cells through other signaling
pathways in vivo, in addition to the feed-forward network
of TGF.
Interestingly, our list of late TGF target genes was en-
riched with signaling components of the WNT pathway
(Figures 2E and 4B). It has been reported that a small por-
tion of breast cancers (∼10%) express 30-fold higher levels
of WNT7B compared with normal or benign breast tissues
(61). In addition, recent data suggest that WNT7B is asso-
ciated with anchorage-independent growth of breast can-
cer cells (62). The importance of crosstalk between TGF
and WNT signaling pathways has been established (63,64).
For acquisition of mesenchymal phenotypes in the breast
TGF and WNT signaling pathways (both canonical and
non-canonical) collaborate to activate mesenchymal genes
and function in an autocrine fashion (65). Similarly, acti-
vation of canonical WNT signaling is required for TGF-
mediated fibrosis (66). Furthermore, it was recently shown
that WNT7A is secreted by breast tumor cells that pro-
mote fibroblast recruitment and conversion to a cancer-
associated fibroblast (CAF) phenotype, which promotes
metastasis (67). WNT7A-mediated CAF activation was me-
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Figure 6. WNT7B promotes breast cancer cell invasion. (A) MCF10A MII mCherry stably expressing control GFP (MII GFP) or ectopic WNT7B-
MYC (MII WNT7B) were injected into the DoC of 48-hpf zebrafish embryos. Left: representative images of zebrafish at 6 days post-injection (dpi). Right:
quantification of invasive cell cluster numbers in GFP or WNT7B-MYC expressing MCF10A MII cells injected zebrafish larvae. (B) Kaplan-Meyer analysis
of overall survival of breast cancer datasets from Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (40); all subtypes, n =
1904; ER+ subjects, n = 1445; ER− subjects, n = 429; luminal A subtype, n = 679; luminal B subtype, n = 461; HER2- subtype, n = 220; basal-like subtype,
n = 199). Survival analysis was performed using a log-rank test. (C) Z-scored expression values of mRNA were obtained with cBioPortal (42,43). (***P
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classical WNT receptor signaling. This suggests that the
JUNB-mediated feed-forward network of TGF is further
stabilized by WNT ligands, resulting in more migratory and
mesenchymal cell phenotypes. In line with this, we found en-
hanced ERK1/2 and SMAD2/3 phosphorylation, and en-
hanced TGF target gene expression in cells stably express-
ing WNT7B (Figure 5F and G), indicating that WNT7B
increases invasion/migration in part by enhancing TGF
type I receptor mediated signaling.
It should be noted that when we examined the role
of canonical WNT signaling, as measured by TCF/LEF-
dependent transcriptional reporter activity, we only found
less than a two-fold increase by WNT7B (Supplementary
Figure S5E). However, MII cells show autocrine TGF (-
related) signaling (16,68) and our RNA sequencing analysis
showed that both WNT7A, WNT7B and WNT9A besides
being induced by TGF (Figure 4C) already show relatively
high basal expression.
In accordance with our analysis, high expression of
WNT7B mRNA was associated with poorer outcomes of
ER+ breast cancer patients in a recent large-scale clinical
study and meta-analysis (Figure 6B and C, and Supplemen-
tary Figure S6A). In line with this, SMAD2/3 ChIP-seq
analysis in the TNBC lines Hs-578-T and BT-549 (Supple-
mentary Figure S6B and C) showed that the binding pat-
terns of SMAD2/3 in these TNBC cell lines are different
from MII cells and, in addition, heterogeneity among the
TNBC cell lines.
In summary, our study presents a model how JUNB me-
diates a TGF signaling feed-forward network in which
WNT7B plays an effector role in specific breast cancer sub-
types to promote breast cancer invasion (Supplementary
Figure S7).
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